CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Returned to the company 10% owner returned 20,000 shares (to the company)
- 4 Option exercise Chief Executive Officer acquired 12,900 shares (option exercise)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Returned to the company 10% owner returned 45,000 shares (to the company)
- 4 Returned to the company 10% owner returned 42,000 shares (to the company)
- 4 Returned to the company 10% owner returned 30,929 shares (to the company)
- 8-K Event Regulation FD disclosure · Other events
- 4 Open-market sale 10% owner sold 40,412 shares at an average $6.03 ($243,834)
- 4 Open-market sale 10% owner sold 28,788 shares at an average $6.92 ($199,087)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Technology Officer sold 14,851 shares at $6.47 ($96,125)
- 4 Open-market sale Chief Executive Officer sold 22,528 shares at $6.47 ($145,815)
- 4 Open-market sale See Remarks sold 9,884 shares at $6.47 ($63,975)
- 4 Open-market sale Chief Medical Officer sold 10,875 shares at $6.47 ($70,390)
Page 10 of 22 · 422 filings